Related references
Note: Only part of the references are listed.A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features
Matthias Zielonka et al.
GENETICS IN MEDICINE (2018)
Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency
Fabian P. S. Yu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1
Edibe Pembegul Yildiz et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2018)
Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months
Melissa P. Wasserstein et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Allogeneic hematopoietic cell transplantation in Farber disease
Karoline Ehlert et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Structural basis for the activation of acid ceramidase
Ahmad Gebai et al.
NATURE COMMUNICATIONS (2018)
Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms
Osamu Kano et al.
SCIENTIFIC REPORTS (2018)
Identification of ASAH1 as a susceptibility gene for familial keloids
Regie Lyn P. Santos-Cortez et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2017)
Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy
Kristin D. Kernohan et al.
HUMAN MUTATION (2017)
Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial
Marc Tardieu et al.
LANCET NEUROLOGY (2017)
Farber disease: design of the first observational and cross-sectional cohort study capturing retrospective and prospective data on the natural history and phenotypic spectrum of patients, including novel methodologies for assessment of disease-specific symptoms
Alexander Solyom et al.
MOLECULAR GENETICS AND METABOLISM (2017)
AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: end-of-Study event free survival and achievement of developmental milestones
J. Mendell et al.
NEUROMUSCULAR DISORDERS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Morbidity and mortality associated with Farber disease and prospects for therapy
Edward H. Schuchman et al.
EXPERT OPINION ON ORPHAN DRUGS (2017)
Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease
Ju Huang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease
Claudia Cozma et al.
SCIENTIFIC REPORTS (2017)
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Richard A. Morgan et al.
CELL STEM CELL (2017)
Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice
Xingxuan He et al.
BBA CLINICAL (2017)
Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities
Jakub Sikora et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy
Shaalee Dworski et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Atypical Presentation of Infantile-Onset Farber Disease with Novel ASAH1 Mutations
Soo Yeon Kim et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2016)
Ceramide Signaling and Metabolism in Pathophysiological States of the Lung
Irina Petrache et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
Early morphological diagnosis of Farber disease
Vanessa Nivaggioni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: a clinical, biochemical and molecular study
Massimiliano Filosto et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2016)
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial
Mario Sessa et al.
LANCET (2016)
Farber disease: Implications of anti-inflammatory treatment
John Mitchell et al.
MOLECULAR GENETICS AND METABOLISM (2016)
Acid ceramidase deficiency leads to multiple skin abnormalities in a mouse model of Farber disease
Lucia Lopez-Vasquez et al.
MOLECULAR GENETICS AND METABOLISM (2016)
Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts
Ruben J. Boado et al.
MOLECULAR PHARMACEUTICS (2016)
Gene therapy's out-of-body experience
Christopher Thomas Scott et al.
NATURE BIOTECHNOLOGY (2016)
Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia
Giulio Genovese et al.
NATURE NEUROSCIENCE (2016)
Eyelid myoclonic status epilepticus: A rare phenotype in spinal muscular atrophy with progressive myoclonic epilepsy associated with ASAH1 gene mutation
Emel Oguz Akarsu et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2016)
Peripheral Osteolysis in Adults Linked to ASAH1 (Acid Ceramidase) Mutations: A New Presentation of Farber's Disease
Luisa Bonafe et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in ASAH1
Guido Rubboli et al.
EPILEPSIA (2015)
Novel use of the lysosomal enzyme acid ceramidase for the treatment of inflammatory lung diseases, including cystic fibrosis
Edward H. Schuchman et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Acid ceramidase deficiency: Clinical implications of an emerging phenotypic spectrum and potential therapies
Alexander Solyom et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency
Melissa P. Wasserstein et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy
Joanna J. Gan et al.
NEUROMUSCULAR DISORDERS (2015)
Mutations in ASAH1 may cause spinal muscular atrophy
A. Behin et al.
NEUROMUSCULAR DISORDERS (2015)
Uniparental disomy as a cause of spinal muscular atrophy and progressive myoclonic epilepsy: Phenotypic homogeneity due to the homozygous c.125C>T mutation in ASAH1
Beatriz G. Giraldez et al.
NEUROMUSCULAR DISORDERS (2015)
Transplantation in inborn errors of metabolism: current considerations and future perspectives
Jaap Jan Boelens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation
M. D. Bashyam et al.
CLINICAL GENETICS (2014)
Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy
D. A. Dyment et al.
CLINICAL GENETICS (2014)
Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa
Yael Pewzner-Jung et al.
EMBO MOLECULAR MEDICINE (2014)
Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation
Andrea Jarisch et al.
EUROPEAN JOURNAL OF PEDIATRICS (2014)
Phenotypic characterization of the spinal muscular atrophy with progressive myoclonus epilepsy syndrome caused by ASAH1 mutations
Swati Sathe et al.
MOLECULAR GENETICS AND METABOLISM (2014)
Farber disease in infancy resembling juvenile idiopathic arthritis: identification of two new mutations and a good early response to allogeneic haematopoietic stem cell transplantation
Marta Torcoletti et al.
RHEUMATOLOGY (2014)
Systemic ceramide accumulation leads to severe and varied pathological consequences
Abdulfatah M. Alayoubi et al.
EMBO MOLECULAR MEDICINE (2013)
Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis
Mikhail M. Kostik et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2013)
Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: Identification of the first large deletion in ASAH1 gene
Mariana Q. Alves et al.
MOLECULAR GENETICS AND METABOLISM (2013)
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Alessandra Biffi et al.
SCIENCE (2013)
Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1
Jie Zhou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
A novel mutation in an atypical presentation of the rare infantile Farber disease
Fatma Al Jasmi
BRAIN & DEVELOPMENT (2012)
Novel V97G ASAH1 mutation found in Farber disease patients: Unique appearance of the disease with an intermediate severity, and marked early involvement of central and peripheral nervous system
Aziza K. Chedrawi et al.
BRAIN & DEVELOPMENT (2012)
Construction of Conditional Acid Ceramidase Knockout Mice and in vivo Effects on Oocyte Development and Fertility
Efrat Eliyahu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2012)
Identification of the N-acylsphingosine amidohydrolase 1 gene (ASAH1) for susceptibility to schizophrenia in a Han Chinese population
Huaihui Zhang et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2012)
Farber disease: A clinical diagnosis
Baris Ekici et al.
JOURNAL OF PEDIATRIC NEUROSCIENCES (2012)
Farber lipogranulomatosis type 1-Late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation
L. Cvitanovic-Sojat et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2011)
Autologous Transplantation of Lentivector/Acid Ceramidase-Transduced Hematopoietic Cells in Nonhuman Primates
Jagdeep S. Walia et al.
HUMAN GENE THERAPY (2011)
Ex vivo gene transfer and correction for cell-based therapies
Luigi Naldini
NATURE REVIEWS GENETICS (2011)
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry
Takhar Kasumov et al.
ANALYTICAL BIOCHEMISTRY (2010)
Leukocyte and plasma N-laurylsphingosine deacylase (ceramidase) in Farber disease
Y. Ben-Yoseph et al.
CLINICAL GENETICS (2010)
Familial Lipogranulomatosis (Farber's disease)
G. H. Amirhakimi et al.
CLINICAL GENETICS (2010)
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
Paul Harmatz et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease
Carmen Bedia et al.
JOURNAL OF LIPID RESEARCH (2010)
RCeveierwamide and ceramide 1-phosphate in health and disease
Lide Arana et al.
LIPIDS IN HEALTH AND DISEASE (2010)
Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease
Patricia Gangoiti et al.
PROGRESS IN LIPID RESEARCH (2010)
Description of a Family with a Novel Progressive Myoclonus Epilepsy and Cognitive Impairment
Edoardo Ferlazzo et al.
MOVEMENT DISORDERS (2009)
Autoproteolytic cleavage and activation of human acid ceramidase
Nataly Shtraizent et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease
Shobha Ramsubir et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Principles of bioactive lipid signalling: lessons from sphingolipids
Yusuf A. Hannun et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Farber's disease type IV presenting with cholestasis and neonatal liver failure: Report of two cases
Asha Willis et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2008)
Acid ceramidase is a novel factor required for early embryo survival
Efrat Eliyahu et al.
FASEB JOURNAL (2007)
Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases
Carmen Bedia et al.
CHEMBIOCHEM (2007)
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease
Beth L. Thurberg et al.
LABORATORY INVESTIGATION (2006)
Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family
Akela Radha Rama Devi et al.
JOURNAL OF HUMAN GENETICS (2006)
The complex life of simple sphingolipids
AH Futerman et al.
EMBO REPORTS (2004)
Successful hematopoietic stem cell transplantation in Farber disease
J Vormoor et al.
JOURNAL OF PEDIATRICS (2004)
Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: potential pathological consequences in age-related neurodegeneration
M Soreghan et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Purification and characterization of recombinant, human acid ceramidase - Catalytic reactions and interactions with acid sphingomyelinase
XX He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The reverse activity of human acid ceramidase
N Okino et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Farber disease diagnosed after liver transplantation
MK Salo et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2003)
Spinal muscular atrophy with progressive myoclonic epilepsy:: Report of new cases and review of the literature
G Haliloglu et al.
NEUROPEDIATRICS (2002)
Mutation analysis of the acid ceramidase gene in Japanese patients with Farber disease
T Muramatsu et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2002)
Surgical treatment of hand disorders in Farber's disease: A case report
H Moritomo et al.
JOURNAL OF HAND SURGERY-AMERICAN VOLUME (2002)
Characterization and direct quantitation of ceramide molecular species from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry
XL Han
ANALYTICAL BIOCHEMISTRY (2002)
Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes
CM Li et al.
GENOMICS (2002)
Human acid ceramidase -: Processing, glycosylation, and lysosomal targeting
K Ferlinz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation
H Hulková et al.
HUMAN MOLECULAR GENETICS (2001)
Enzyme-replacement therapy in mucopolysaccharidosis I.
ED Kakkis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular analysis of acid ceramidase deficiency in patients with Farber disease
J Bar et al.
HUMAN MUTATION (2001)
Intrauterine fetal death due to Farber disease: Case report
G van Lijnschoten et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2000)
Current methods for the identification and quantitation of ceramides: An overview
AE Cremesti et al.
LIPIDS (2000)
Human acid ceramidase gene: Novel mutations in Farber disease
ZJ Zhang et al.
MOLECULAR GENETICS AND METABOLISM (2000)
Bone marrow transplantation for infantile ceramidase deficiency (Farber disease)
AM Yeager et al.
BONE MARROW TRANSPLANTATION (2000)
Liquid chromatography-electrospray mass spectrometry and tandem mass spectrometry of ceramides
K Raith et al.
ANALYTICA CHIMICA ACTA (2000)
Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease
F Farina et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2000)
Share Paper
